A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea

Trial Profile

A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Azelaic acid (Primary)
  • Indications Rosacea
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 31 Jul 2015 According to Foamix media release, the US FDA has approved azalaic acid (Finacea) foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.
    • 24 Jul 2014 Primary endpoint has been met. (Therapeutic success rate - investigators global assessment)
    • 24 Jul 2014 Primary endpoint has been met. (Change in inflammatory lesion count)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top